Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve Cognitive function in Schizophrenia

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qingyun Yin
• Treatments: Antipsychotic Agents; Aripiprazole; Olanzapine; Quetiapine Fumarate; Risperidone; Tandospirone; Ziprasidone

Criteria

Inclusion Criteria:

• Diagnostic and Statistical Manual of Mental Disorders-IV Edition (DSM-IV) diagnostic criteria for schizophrenia patients.

• 18-65 years (including 18 and 65), male or female.

• Treated with a stable dose of an AAPD for at least three months.

• Informed consent was obtained (if the patient is in the acute phase of schizophrenia, does not have the capacity, their guardians need sign informed consent).

• PANSS negative score ≤60.

Exclusion Criteria:

• Combined AxisⅠmental illness other than schizophrenia;

• Taking a mood stabilizer, antidepressants, anticholinergic or anxiolytic drugs, and other drugs improve cognitive function;

• Suicidal tendencies;

• Have severe or unstable heart, liver, kidney, endocrine, blood and other medical disease patients

• Clinically significant ECG or laboratory abnormalities were

• Glaucoma and epilepsy;

• Unsupervised or unable to take prescribed medication;

• History of alcohol and drug abuse;

• Allergic;

• Pregnant or lactating woman;

• Patients participate in other clinical trials during a month;